Key Points
- Castle Biosciences COO Kristen Oelschlager sold 8,586 shares on July 1 at an average price of $24.42, for proceeds of about $209,670. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Oelschlager still owned 21,874 shares, and the sale reduced her position by 28.19%. The filing was disclosed with the SEC.
- The company recently reported quarterly EPS of ($0.49), matching expectations, while revenue of $84.23 million came in above estimates. Analysts currently rate CSTL Moderate Buy with an average price target of $42.43.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 6,214 shares of Castle Biosciences stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $24.29, for a total value of $150,938.06. Following the completion of the sale, the insider owned 21,479 shares of the company's stock, valued at $521,724.91. The trade was a 22.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Stock Down 0.5%
Shares of Castle Biosciences stock opened at $24.09 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. The stock has a market cap of $730.50 million, a price-to-earnings ratio of -55.02 and a beta of 1.00. The firm's 50-day moving average is $21.54 and its two-hundred day moving average is $28.56. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $44.28.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. The firm had revenue of $84.23 million during the quarter, compared to analysts' expectations of $79.23 million. As a group, research analysts expect that Castle Biosciences, Inc. will post -1.56 earnings per share for the current fiscal year.
Institutional Trading of Castle Biosciences
Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Castle Biosciences by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company's stock worth $85,573,000 after buying an additional 27,511 shares during the last quarter. RTW Investments LP acquired a new stake in Castle Biosciences in the fourth quarter worth about $82,283,000. Principal Financial Group Inc. boosted its holdings in Castle Biosciences by 0.7% in the fourth quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company's stock worth $70,317,000 after acquiring an additional 13,289 shares in the last quarter. Portolan Capital Management LLC grew its stake in shares of Castle Biosciences by 1.7% during the third quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company's stock worth $34,499,000 after acquiring an additional 25,539 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Castle Biosciences by 7.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company's stock worth $33,564,000 after acquiring an additional 96,084 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. KeyCorp set a $35.00 target price on Castle Biosciences in a report on Friday, May 29th. Roth Mkm initiated coverage on Castle Biosciences in a report on Wednesday, June 24th. They issued a "buy" rating and a $40.00 price target on the stock. Robert W. Baird decreased their price objective on Castle Biosciences from $44.00 to $43.00 and set an "outperform" rating for the company in a research note on Thursday, May 7th. Weiss Ratings cut Castle Biosciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, June 1st. Finally, BTIG Research dropped their price objective on Castle Biosciences from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Castle Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $42.43.
Read Our Latest Research Report on CSTL
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
